Difference between revisions of "De Jesus-Acosta A, et al. Invest. N. Drugs (2014) cited as Ref 586 in DOI: 10.1038/s41392-020-0110-5 (Q9849)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created claim: DOI Identifier (P138): 10.1007/s10637-014-0083-8, #quickstatements; #temporary_batch_1590000649558)
(‎Created claim: Page(s) (P105): 739-745, #quickstatements; #temporary_batch_1590074839150)
 
(4 intermediate revisions by the same user not shown)
Property / Publication Date
 +
2014
Timestamp+2014-01-01T00:00:00Z
Timezone+00:00
CalendarGregorian
Precision1 year
Before0
After0
Property / Publication Date: 2014 / rank
 +
Normal rank
Property / Published In Name String
 +
Invest. N. Drugs
Property / Published In Name String: Invest. N. Drugs / rank
 +
Normal rank
Property / Volume
 +
32
Property / Volume: 32 / rank
 +
Normal rank
Property / title
 +
A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma (English)
Property / title: A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma (English) / rank
 +
Normal rank
Property / Page(s)
 +
739-745
Property / Page(s): 739-745 / rank
 +
Normal rank

Latest revision as of 15:46, 21 May 2020

Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language Label Description Also known as
English
De Jesus-Acosta A, et al. Invest. N. Drugs (2014) cited as Ref 586 in DOI: 10.1038/s41392-020-0110-5
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

    Statements

    De Jesus-Acosta A
    0 references
    2014
    0 references
    Invest. N. Drugs
    0 references
    32
    0 references
    A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma (English)
    0 references
    739-745
    0 references